Recurrent Plasma Cell Myeloma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma - 2022
Withdrawn
  • Recurrent Plasma Cell Myeloma
  • Daratumumab
  • +2 more
  • Wichita, Kansas
  • +3 more
2022-04-07
Apr 7, 2022
N
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1423 more
2022-04-06
Apr 6, 2022
N
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Recruiting
  • Plasmacytoma
  • +2 more
  • Sacramento, California
  • +5 more
2022-04-06
Apr 6, 2022
N
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Recruiting
  • Lymphoma
  • +6 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +139 more
2022-04-05
Apr 5, 2022
R
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Not yet recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Behavioral Intervention
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-03-28
Mar 28, 2022
A
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
2022-03-23
Mar 23, 2022
N
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • New Haven, Connecticut
  • +8 more
2022-03-29
Mar 29, 2022
F
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-14
Mar 14, 2022
M
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Suspended
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-22
Mar 22, 2022
M
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Bone Marrow Biopsy
  • +3 more
  • Phoenix, Arizona
  • +2 more
2022-03-22
Mar 22, 2022
M
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Scottsdale, Arizona
  • +2 more
2022-03-23
Mar 23, 2022
C
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
2022-03-17
Mar 17, 2022
U
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022
U
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022
O
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-03-11
Mar 11, 2022
E
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • ISS Stage I Plasma Cell Myeloma
  • +4 more
  • Pembrolizumab
  • Radiation Therapy
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
2022-03-02
Mar 2, 2022
F
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Not yet recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-01
Mar 1, 2022
N
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma - 2020
Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
2022-02-10
Feb 10, 2022
C
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Active, not recruiting
  • Acute Leukemia
  • +14 more
  • Duarte, California
    City of Hope Medical Center
2022-02-17
Feb 17, 2022
O
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +58 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-02-16
Feb 16, 2022
M
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • t(11;14)
  • Ann Arbor, Michigan
  • +2 more
2022-01-28
Jan 28, 2022
M
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +13 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
M
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-02-03
Feb 3, 2022
M
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma
Recruiting
  • Myelodysplastic Syndrome
  • +16 more
  • Computed Tomography
  • +6 more
  • Scottsdale, Arizona
  • +2 more
2022-02-03
Feb 3, 2022
F
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies - 2021
Terminated
  • Acute Biphenotypic Leukemia
  • +29 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022